Advanced/Recurrent Ovarian cancer research hub

A Master Protocol Phase I/II Study to Investigate Biomarker‑Guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy for the Treatment of Participants with Advanced/Recurrent Ovarian Cancer (Ovarian Platform)

This study is testing a new drug called Saruparib for women with advanced or recurrent ovarian cancer. Researchers want to see how safe the drug is and if it can shrink tumors or control cancer growth. It's an early-stage study, combining two phases to learn about the drug's effects.